Viridian Therapeutics Inc. | Small-cap | Healthcare

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 72.0K
Operating Income -93.9M -130,369.44%
Net Income -86.9M -120,711.11%
EPS (Diluted) $-0.87

Balance Sheet Metrics

Total Assets 661.0M
Total Liabilities 56.5M
Shareholders Equity 604.5M
Debt to Equity 0.09

Cash Flow Metrics

Operating Cash Flow -74.8M
Free Cash Flow -92.7M

Revenue & Profitability Trend

Viridian Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i302.0K314.0K1.8M3.0M1.0M
Cost of Goods Sold i-----
Gross Profit i-----
Gross Margin % i0.0%0.0%0.0%0.0%0.0%
Operating Expenses
Research & Development i238.3M159.8M100.9M56.9M28.3M
Selling, General & Administrative i61.1M95.0M35.2M25.8M13.3M
Other Operating Expenses i-----
Total Operating Expenses i299.3M254.8M136.1M82.7M41.6M
Operating Income i-299.0M-254.4M-134.3M-79.7M-40.5M
Operating Margin % i-99,018.2%-81,035.0%-7,579.2%-2,690.8%-3,859.0%
Non-Operating Items
Interest Income i32.1M18.6M4.9M318.0K173.0K
Interest Expense i3.0M1.8M486.0K3.0K508.0K
Other Non-Operating Income-----69.9M
Pre-tax Income i-269.9M-237.7M-129.9M-79.4M-110.7M
Income Tax i-----
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-269.9M-237.7M-129.9M-79.4M-110.7M
Net Margin % i-89,387.1%-75,711.5%-7,329.2%-2,680.2%-10,544.3%
Key Metrics
EBITDA i-266.4M-235.4M-129.1M-79.3M-40.1M
EPS (Basic) i$-3.07$-5.31$-4.05$-6.66$-31.13
EPS (Diluted) i$-3.07$-5.31$-4.05$-6.66$-31.13
Basic Shares Outstanding i678858314475547532087293119187123557065
Diluted Shares Outstanding i678858314475547532087293119187123557065

Income Statement Trend

Viridian Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i99.6M102.8M155.6M42.3M45.9M
Short-term Investments i618.0M374.5M269.0M154.7M81.7M
Accounts Receivable i-----
Inventory i-----
Other Current Assets20.9M9.0M6.5M2.7M2.0M
Total Current Assets i738.5M486.5M431.2M200.2M129.6M
Non-Current Assets
Property, Plant & Equipment i3.3M2.8M2.8M2.5M3.0M
Goodwill i-----
Intangible Assets i-----
Long-term Investments-----
Other Non-Current Assets501.0K604.0K982.0K1.5M1.7M
Total Non-Current Assets i3.9M3.9M3.9M3.5M1.6M
Total Assets i742.4M490.4M435.1M203.7M131.3M
Liabilities
Current Liabilities
Accounts Payable i2.1M2.2M14.2M2.3M670.0K
Short-term Debt i513.0K843.0K613.0K520.0K455.0K
Current Portion of Long-term Debt-----
Other Current Liabilities100.0K100.0K100.0K100.0K100.0K
Total Current Liabilities i47.9M26.6M33.3M13.6M10.7M
Non-Current Liabilities
Long-term Debt i20.6M20.2M4.6M--
Deferred Tax Liabilities i-----
Other Non-Current Liabilities2.0M989.0K1.2M1.2M43.0K
Total Non-Current Liabilities i22.9M21.8M6.7M2.4M544.0K
Total Liabilities i70.8M48.4M40.0M16.0M11.2M
Equity
Common Stock i810.0K540.0K414.0K239.0K42.0K
Retained Earnings i-995.9M-725.9M-488.2M-358.3M-278.9M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i671.6M442.0M395.1M187.7M120.0M
Key Metrics
Total Debt i21.1M21.0M5.3M520.0K455.0K
Working Capital i690.6M459.8M397.8M186.5M118.9M

Balance Sheet Composition

Viridian Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-269.9M-237.7M-129.9M-79.4M-110.7M
Depreciation & Amortization i540.0K522.0K255.0K120.0K239.0K
Stock-Based Compensation i42.2M67.2M19.8M14.5M3.6M
Working Capital Changes i-259.0K-12.3M11.6M1.8M-426.0K
Operating Cash Flow i-227.0M-175.8M-98.0M-55.5M-34.7M
Investing Activities
Capital Expenditures i-511.0K-898.0K-797.0K-259.0K-42.0K
Acquisitions i---029.4M
Investment Purchases i-695.1M-407.9M-223.3M-188.4M-81.8M
Investment Sales i466.9M314.5M108.9M114.4M2.0M
Investing Cash Flow i-228.7M-94.3M-115.1M-74.3M-50.5M
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i015.0M5.0M01.7M
Debt Repayment i---0-10.3M
Financing Cash Flow i451.7M203.9M318.4M122.9M101.3M
Free Cash Flow i-232.8M-185.1M-94.6M-54.9M-29.8M
Net Change in Cash i-3.9M-66.1M105.2M-6.9M16.1M

Cash Flow Trend

Viridian Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -5.91
Forward P/E -4.19
Price to Book 4.38
Price to Sales 4,685.55
PEG Ratio 3.01

Profitability Ratios

Profit Margin 0.00%
Operating Margin -142,356.00%
Return on Equity -65.88%
Return on Assets -39.77%

Financial Health

Current Ratio 11.01
Debt to Equity 4.48
Beta 0.48

Per Share Data

EPS (TTM) $-3.57
Book Value per Share $4.00
Revenue per Share $0.00

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
vrdn1.4B-5.914.38-65.88%0.00%4.48
Vertex 100.2B27.775.8322.77%31.86%8.89
Regeneron 62.9B14.952.0615.34%31.37%9.04
Cg Oncology 2.1B-19.093.06-12.00%0.00%0.15
Adaptive 1.9B-12.0410.69-57.60%-59.07%121.39
Vericel 1.8B255.215.872.59%2.85%32.74

Financial data is updated regularly. All figures are in the company's reporting currency.